Literature DB >> 3790409

Inhibition of antipyrine metabolism by interferon.

S J Williams, G C Farrell.   

Abstract

Antipyrine clearance was measured before and 1 day after administration of a single intramuscular dose of recombinant human leukocyte alpha A interferon. In the nine patients studied, antipyrine clearance was reduced after interferon from 0.49 (0.21-1.13) ml kg-1 min-1 (median (range)) to 0.41 (0.20-1.07) ml kg-1 min-1, P less than 0.01. In individual patients, the decrement in antipyrine clearance was variable, ranging from 5-47% (median, 16%). This study provides the first direct evidence that interferon inhibits hepatic oxidative drug metabolism in humans and alerts clinicians to the possibility of potentially toxic drug-drug interactions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3790409      PMCID: PMC1401186          DOI: 10.1111/j.1365-2125.1986.tb02943.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Relationship between the antiviral effects of interferons and their abilities to depress cytochrome P-450.

Authors:  K W Renton; G Singh; N Stebbing
Journal:  Biochem Pharmacol       Date:  1984-12-01       Impact factor: 5.858

3.  Alpha interferon for induction of remission in hairy-cell leukemia.

Authors:  J R Quesada; J Reuben; J T Manning; E M Hersh; J U Gutterman
Journal:  N Engl J Med       Date:  1984-01-05       Impact factor: 91.245

4.  Effect of interferon inducing agents (polyriboinosinic acid . polyribocytidylic acid and tilorone) on the heme turnover of hepatic cytochrome P-450.

Authors:  R el Azhary; K W Renton; G J Mannering
Journal:  Mol Pharmacol       Date:  1980-05       Impact factor: 4.436

5.  Interferon reduces hepatic drug metabolism in vivo in mice.

Authors:  G Taylor; B J Marafino; J A Moore; V Gurley; T F Blaschke
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

6.  Recombinant leukocyte a interferon treatment in patients with chronic hepatitis B virus infection. Pharmacokinetics, tolerance, and biologic effects.

Authors:  M Omata; F Imazeki; O Yokosuka; Y Ito; K Uchiumi; J Mori; K Okuda
Journal:  Gastroenterology       Date:  1985-04       Impact factor: 22.682

7.  Accuracy and clinical utility of simplified tests of antipyrine metabolism.

Authors:  G C Farrell; L Zaluzny
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

8.  Inhibition of the synthesis of hepatic cytochrome P-450 by the interferon-inducing agent poly rI.rCi.

Authors:  G Singh; K W Renton
Journal:  Can J Physiol Pharmacol       Date:  1984-04       Impact factor: 2.273

9.  Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma.

Authors:  J U Gutterman; G R Blumenschein; R Alexanian; H Y Yap; A U Buzdar; F Cabanillas; G N Hortobagyi; E M Hersh; S L Rasmussen; M Harmon; M Kramer; S Pestka
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

10.  Cimetidine impairs the elimination of theophylline and antipyrine.

Authors:  R K Roberts; J Grice; L Wood; V Petroff; C McGuffie
Journal:  Gastroenterology       Date:  1981-07       Impact factor: 22.682

View more
  23 in total

Review 1.  The role of pharmacokinetics in the development of biotechnologically derived agents.

Authors:  R J Wills; B L Ferraiolo
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of interferons.

Authors:  R J Wills
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  Depression of drug metabolizing activity in the human liver by interferon-alpha.

Authors:  H Okuno; Y Kitao; M Takasu; H Kano; K Kunieda; T Seki; Y Shiozaki; Y Sameshima
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 4.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  M T Kinirons; P Crome
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 5.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

6.  The effect of pneumococcal vaccine on the disposition of theophylline.

Authors:  G C Cupit; T H Self; W B Bekemeyer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.

Authors:  Pankajini Mallick; Guncha Taneja; Bhagavatula Moorthy; Romi Ghose
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-22       Impact factor: 4.481

8.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

9.  Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.

Authors:  Karin Hellman; Ewa Roos; Anna Osterlund; Anneli Wahlberg; Lars L Gustafsson; Leif Bertilsson; Sten Fredrikson
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

10.  Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure.

Authors:  P Toft; L Heslet; M Hansen; N A Klitgaard
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.